Real-World Effectiveness and Safety of Tildrakizumab in Patients With Moderate-to-Severe Psoriasis: Week 28 Interim Analysis of a Phase 4 Study

August 2023 | Volume 22 | Issue 8 | 754 | Copyright © August 2023


Published online July 25, 2023

Jayme Heim MSN FNP-BCa, J. Gabriel Vasquez MDa, Brad Schenkel MSb, Neal Bhatia MDc

aWest Michigan Dermatology, Grandville, MI
bSun Pharmaceutical Industries, Inc., Princeton, NJ
cTherapeutics Clinical Research, San Diego, CA



(MedDRA) System Organ Class and Preferred Term and summarized by frequency and severity. The severity of an AE was categorized as mild, moderate, or severe based on whether it interfered significantly with the patient's normal functioning.

RESULTS

Patients
Of the 55 patients enrolled, 28 (50.9%) were male, and 52 (94.5%) were White, with a mean ± standard deviation (SD) age of 48.6 ± 15.3 years. The demographic and baseline characteristics of the ITT population are summarized in Table 1. At week 28, 52/55 (94.5%) patients were available for efficacy assessments. Safety assessments included all 55 enrolled patients. One patient discontinued due to a TEAE.